Last reviewed · How we verify

NLS-2 — Competitive Intelligence Brief

NLS-2 (NLS-2) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Orexin-2 receptor agonist. Area: Neurology.

phase 3 Orexin-2 receptor agonist Orexin-2 receptor (OX2R) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

NLS-2 (NLS-2) — NLS Pharmaceutics. NLS-2 is a selective orexin-2 receptor agonist that promotes wakefulness by enhancing neural signaling in brain regions responsible for arousal and alertness.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NLS-2 TARGET NLS-2 NLS Pharmaceutics phase 3 Orexin-2 receptor agonist Orexin-2 receptor (OX2R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Orexin-2 receptor agonist class)

  1. NLS Pharmaceutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NLS-2 — Competitive Intelligence Brief. https://druglandscape.com/ci/nls-2. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: